Results 121 to 130 of about 60,030 (268)

N. Paul Rosman, M.D. (1934–2026)

open access: yes
Annals of the Child Neurology Society, EarlyView.
Alcy Torres   +3 more
wiley   +1 more source

Strategic Priorities for Advancing Eating Disorder Risk Reduction: A Narrative Review

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Despite decades of advances in treatment, eating disorders continue to impose substantial individual and societal burden, underscoring the need for earlier and more effective risk reduction. Prevention research has expanded considerably, producing a wide range of approaches that target modifiable risk factors, build individual coping skills ...
Hannah K. Jarman
wiley   +1 more source

The Weight of the Number: Perceptions and Practices Surrounding Expected Body Weight Disclosure in Eating Disorder Treatment

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Expected body weight (EBW) determination is common in eating disorder (ED) treatment, yet no evidence‐based guidelines exist for how to discuss EBWs with patients. Clinicians have previously conceptualized these discussions as therapeutic exposures targeting fear of weight gain.
Agatha A. Laboe   +6 more
wiley   +1 more source

Radical Listening as a Governance Innovation: Integrating Planetary Health and Community‐Led Forest Conservation in Indonesia

open access: yesEnvironmental Policy and Governance, EarlyView.
ABSTRACT While REDD+ prioritizes carbon sequestration, its narrow focus often overlooks forest‐health linkages critical to community well‐being. This paper examines the holistic model of Health in Harmony (HIH) and Alam Sehat Lestari (ASRI), which integrates forest conservation with healthcare through radical listening—a decolonial community engagement
Angie Hsu   +3 more
wiley   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy